ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 520

The HAQ Reversible and Irreversible Components Measuring Function in Rheumatoid Arthritis

Mary Bell1, Jacqueline Stewart2, Boulos Haraoui3, Edward Keystone4, Philip Baer5, Pauline Boulos6, Dalton Sholter7, Algis Jovaisas8, Emmanouil Rampakakis9, Julie Vaillancourt10, Cathy Tkaczyk11, Karina Maslova12, Brendan Osborne11, Allen J Lehman12 and Francois Nantel13, 1University of Toronto, Toronto, ON, Canada, 2Penticton Regional Hospital, Penticton, BC, Canada, 3University of Montreal, Montreal, QC, Canada, 4Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada, 5Independent Rheumatology Practice, Scarborough, ON, Canada, 6Rheumatology, McMaster University, Hamilton, ON, Canada, 7University of Alberta, Edmonton, AB, Canada, 8Capital North Therapeutics & Research, Ottawa, ON, Canada, 9JSS Medical Research, St-Laurent, QC, Canada, 10JSS Medical Research, Montreal, QC, Canada, 11Medical Affairs, Janssen Inc., Toronto, ON, Canada, 12Janssen Inc., Toronto, ON, Canada, 1319 Green belt Dr, Janssen Inc., Toronto, ON, Canada

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Health Assessment Questionnaire and anti-TNF therapy

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2016

Title: Rheumatoid Arthritis – Clinical Aspects - Poster I: Clinical Characteristics/Presentation/Prognosis

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:   Rheumatoid arthritis (RA) functional impairment is composed of reversible and irreversible components. The aim of this analysis was to assess the reversible and irreversible components of RA physical function as measured by the Health Assessment Questionnaire (HAQ) in Canadian routine clinical practice.

Methods:   BioTRAC is an ongoing, prospective registry of patients initiating treatment with IFX or GLM for RA, ankylosing spondylitis, or psoriatic arthritis. Eligible participants for this analysis included RA patients treated with IFX enrolled since 2002 or with GLM enrolled since 2010, who had a HAQ >0 at baseline and at least one follow-up assessment with known HAQ score at remission or achievement of low disease activity (LDA). Remission was defined as SDAI ≤3.3, CDAI≤2.8, DAS28 <2.6, or achievement of the following four criteria: SJC ≤1, TJC ≤3, CRP level ≤0.8 mg/dL and MdGA ≤15mm. Low disease activity was defined as SDAI ≤11.0, CDAI ≤10.0 or DAS28 ≤3.2. HAQ scores at the time of RA remission or achievement of LDA represented the irreversible component of the disease functional limitation, namely the residual HAQ score, while the difference in HAQ scores from baseline to remission or LDA corresponded to the reversible component. In addition, the reversibility of HAQ score was determined as the relative improvement in baseline HAQ score at the time of remission or achievement of LDA and, the fraction of HAQ irreversibility was calculated as the residual HAQ score divided by the maximum possible HAQ score. Descriptive statistics were produced for HAQ reversible and irreversible parameters.  The correlation of disease duration with the HAQ irreversible component was described with the Pearson’s correlation coefficient. Multivariate linear regressions adjusted for age, gender, anti-TNF, baseline disease duration and HAQ score at baseline were performed to assess the impact of the type of coverage (private and public) on reversible and irreversible components of the disease. Level of statistical significance was set to 0.05.

Results:   There were 753 patients included in this analysis (499 patients were on IFX and 254 on GLM) with a mean (SD) age of 56.4 (13.4) years, disease duration since diagnosis of 8.7 (9.3) years and HAQ score of 1.5 (0.7) at treatment initiation. The majority of patients were females (74.8%). At treatment initiation, 356 (47.8%) and 289 (38.8%) patients were on public and private drug coverage, respectively. The HAQ reversible and irreversible components in RA are presented in Table 1. Variation in the reversibility of HAQ score was observed among RA patients depending on the target outcome used for the calculation, with 44.8% reversibility reported based on DAS28 remission to 57.6% with SDAI remission and, from 33.1% based on CDAI-LDA to 36.4% with SDAI-LDA. Weak correlations between disease duration and HAQ irreversible component were observed for all the target outcomes with Pearson’s coefficients varying from 0.105 based on derived definition of remission to 0.270 with CDAI remission and, from 0.119 based on SDAI-LDA to 0.202 with DAS28-LDA. Upon adjustment for age, gender, anti-TNF agent, baseline disease duration, and HAQ score at baseline, patients on private insurance were found to have significantly greater HAQ reversibility when assessed with SDAI remission (β= -27.39; P=0.029) and derived definition of remission (β= -17.94; P=0.036) than patients on public coverage. Coverage type was not found to have an impact the fraction of HAQ irreversibility and the irreversible component. Table 1:HAQ Reversible and Irreversible Components in Rheumatoid Arthritis.  

Target Outcomes N

Months from BL to Target, Mean (SD)

Change in HAQ score from BL to Target (Reversible component), mean (SD)

% Reversibility of BL HAQ score, mean (SD)

Residual HAQ score (Irreversible component), mean (SD) Fraction of HAQ Irreversibility, mean (SD)
DAS28 remission 426 13.56 (13.24) -0.67 (0.68) -44.78 (45.59) 0.76 (0.67) 0.25 (0.22)
DAS28 low disease activity 573 10.73 (11.22) -0.58 (0.67) -34.97 (54.00) 0.86 (0.67) 0.29 (0.22)
CDAI remission 306 17.51 (14.00) -0.84 (0.69) -54.69 (53.03) 0.57 (0.56) 0.19 (0.19)
CDAI low disease activity 699 9.65 (9.27) -0.55 (0.63) -33.09 (52.32) 0.94 (0.70) 0.31 (0.23)
SDAI remission 266 17.14 (14.25) -0.89 (0.70) -57.56 (50.83) 0.57 (0.57) 0.19 (0.19)
SDAI low disease activity 594 10.90 (10.59) -0.60 (0.65) -36.39 (54.08) 0.89 (0.69) 0.30 (0.23)
Derived definition of remission 479 13.11 (12.25) -0.60 (0.67) -37.72 (53.41) 0.88 (0.71) 0.29 (0.24)

   

Conclusion:   The results of this Canadian longitudinal observational study show variability in the proportions of reversibility and suggest that patients on private insurance at treatment initiation have a greater reversibility of RA functional impairment than patients on provincial coverage. However, the type of coverage did not have an impact on irreversible components of the disease.


Disclosure: M. Bell, Paid Consultant of Janssen Inc., Canada, 5; J. Stewart, Janssen Inc., 5; B. Haraoui, Janssen Inc., 5; E. Keystone, Abbott, AstraZeneca, Biotest, BMS, Crescendo, Hoffmann-LaRoche, Genentech, Janssen Inc, Eli Lilly and Company, Merck, Pfizer, UCB, 5; P. Baer, Janssen Inc., 5; P. Boulos, Janssen Inc., 5; D. Sholter, Janssen Inc., 5; A. Jovaisas, Janssen Inc., 5; E. Rampakakis, employee of JSS Medical Research, 3; J. Vaillancourt, JSS Research, 3; C. Tkaczyk, Employee of Janssen Inc., 3; K. Maslova, Employee of Janssen Inc., 3; B. Osborne, Employee of Janssen Inc., 3; A. J. Lehman, Employee of Janssen Inc., 3; F. Nantel, Employee of Janssen Inc., 3.

To cite this abstract in AMA style:

Bell M, Stewart J, Haraoui B, Keystone E, Baer P, Boulos P, Sholter D, Jovaisas A, Rampakakis E, Vaillancourt J, Tkaczyk C, Maslova K, Osborne B, Lehman AJ, Nantel F. The HAQ Reversible and Irreversible Components Measuring Function in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/the-haq-reversible-and-irreversible-components-measuring-function-in-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-haq-reversible-and-irreversible-components-measuring-function-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology